OncoMatch/Clinical Trials/NCT06439771
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Is NCT06439771 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies YL202 should be intravenously infused for locally advanced or metastatic breast cancer.
Treatment: YL202 should be intravenously infused — This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 HR-negative
HR-negative
Required: HER2 (ERBB2) HER2-negative
HER2-negative
Required: ESR1 HR-positive
HR positive
Required: HER2 (ERBB2) HER2-Zero-expression
HER2-Zero-expression
Required: HER2 (ERBB2) HER2-Low-expression
HER2-Low-expression
Disease stage
Required: Stage III, IV
Demographics
Prior therapy
Must have received: antibody-drug conjugate (HER2-ADC, TROP2-ADC)
previously failed treatments of HER2-ADC or TROP2-ADC
Cannot have received: HER3-targeted therapy
prior treatment with an agent targeting HER3
Cannot have received: topoisomerase I inhibitor
prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor
Lab requirements
Blood counts
adequate organ and bone marrow function within 7 days prior to the first dose
Kidney function
Liver function
Have Adequate organ and bone marrow function within 7 days prior to the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06439771 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HER3-targeted therapy, topoisomerase I inhibitor disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 HR-negative is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 HER2-negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 HR-positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify